Von willebrand factor in polymyalgia rheumatica and giant cell arteritis

Clinical and Experimental Rheumatology

Volumn 18, Issue SUPPL. 20, 2000, Pages

  Uddhammar, A C ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Giant cell arteritis; Polymyalgia rheumatica; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; GIANT CELL ARTERITIS; INFLAMMATION; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA;

HUMANS; POLYMYALGIA RHEUMATICA; TEMPORAL ARTERITIS; VON WILLEBRAND FACTOR;

EID: 0033847468     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Von Willebrand factor
2. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells
3. Autocrine regulation of endothelial exocystosis: Von Willebrand factor release is induced by prostacyklin in cultured endothelial cells
4. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment
5. Atherosclerosis - An inflammatory disease
6. Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders?
7. Von Willebrand factor, tissue plasminogen activator and dehydroepiandrosterone sulphate predict cardiovascular death in a 10-year follow up of survivors of acute myocardial infarction
8. Hemostatic factor and the risk of myocardial infarction or sudden death in patients with angina pectoris
9. Von Willebrand factor and plasminogen activator inhibition in giant cell arteritis
10. Plasminogen activator inhibitor and Von Willebrand factor in polymyalgia rheumatica
11. Von Willebrand factor in the outcome of temporal arteritis
12. Corticosteroid requirements in polymyalgia rheumatica
13. Long-term follow up of Von Willebrand factor and plasminogen activator inhibitor-1 in patients with polymyalgiarheumatica
14. Functional profile of tissue infiltrating and circulating CD68+ cells in giant cell arteritis: Evidence for two components of the disease
15. Biochemical and biological aspects of the plasminogen activation system
16. ABO blood group genotype and plasma yon Willebrand factor in normal individuals
17. Temporal arteritis. A 25-year epidemiologic clinical and pathologic study
18. Excess mortality in giant cell arteritis
19. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy
20. Epidemiology and mortality in 220 patients with polymyalgia rheumatica